Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
1 hedge funds and large institutions have $2.54K invested in Intra-Cellular Therapies Inc. in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
100% less capital invested
Capital invested by funds: $4.15M → $2.54K (-$4.15M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$4.09M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$60.1K |
ITCI Hedge Fund Activity: Q3 2025 in Review
1 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2025, worth a combined $2.54K — down 100% from $4.15M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ITCI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $4.09M sold.
- 1 institutional investor held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2025, down from 3 in Q2 2025.
- Funds reported $2.54K of Intra-Cellular Therapies Inc. stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2025 and 2 closed out, a net change of -2 holders.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2025 was DekaBank Deutsche Girozentrale, an estimated $4.09M sold.
Based on aggregated 13F filings for Q3 2025.